Eprosartan chemical structure
Find information on thousands of medical conditions and prescription drugs.

Eprosartan

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed as Teveten® by the Biovail Corporation in the United States and by Solvay Pharmaceuticals elsewhere. It is sometimes paired with hydrochlorothiazide. more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

The drug acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than ACE inhibitors, especially among the elderly.

Read more at Wikipedia.org


[List your site here Free!]


ARB outperforms calcium antagonist in secondary stroke prevention
From Geriatrics, 4/1/05

The angiotensin receptor blocker, eprosartan, is associated with fewer adverse cardiovascular/cerebrovascular events, compared with the calcium antagonist, nitrendipine, in hypertensive patients with a recent history of stroke, Hans-Christian Diener, MD, said.

In the Morbidity and Mortality after Stroke (MOSES) trial, the agents were compared as secondary stroke prophylaxis in 1,405 hypertensive patients (mean age: 68 years) who had suffered a cerebral event in the preceding 24 months. Patients were randomized to eprosartan, 600 mg/d, or nitrendipine, 10 mg/d.

During the 2.5-year follow-up, achieved blood pressures were comparable between the two groups: mean blood pressure in patients randomized to eprosartan decreased from 150.7/84 mm Hg at baseline to 137.5/80.8 mm Hg at the final follow-up; mean blood pressure in patients assigned to nitrendipine declined from 152.0/87.2 mm Hg to 136.0/80.2 mm Hg.

The primary endpoint--the composite of total mortality and all cardiac and cerebrovascular events--was reached by 206 patients assigned to eprosartan and 255 assigned to nitrendipine, corresponding to a 21% reduction with eprosartan (p=0.014). This was the first clinical trial in secondary stroke prevention to compare two active treatments, noted Dr. Diener, chairman and professor of neurology, University of Essen, Germany.

COPYRIGHT 2005 Advanstar Communications, Inc.
COPYRIGHT 2005 Gale Group

Return to Eprosartan
Home Contact Resources Exchange Links ebay